Jonathan Passeri, MD
Cardiovascular Disease · Boston, MANPI 1477534725
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,300 of the $35,933 with a category attached, or 64.8%. Abbott accounts for 61.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $20,930 and has fallen 78.2% since, to $4,561 in 2025.
Across 77 payments — averaging $466.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$22K
- Edwards Lifesciences$8K
- Medtronic$6K
- Philips North America LLC$150
- Boston Scientific$86
Across 6 payments — averaging $3175.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$19K
What the payments were for
- Consulting fees$4,72513%
- Speaking & faculty fees$23,30065%
- Travel & lodging$5,45315%
- Food & beverage$2,4557%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 44 | $22,182 |
| Edwards Lifesciences | 15 | $7,671 |
| Medtronic(2 entities) | 16 | $5,843 |
| Philips North America LLC | 1 | $150 |
| Boston Scientific | 1 | $86 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mitra Clip system$21,550
- CoreValve Evolut$2,634
- APOLLOTM$667
- Edwards SAPIEN 3 Transcatheter Heart Valve$364
- EVOQUE$184
- EPIQ 7C$150
- Diamondback Coronary$138
- MitraClip$134
How this compares
$35,933 in reported general payments places this provider in the 85th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 129 | $187,177 |
| JardianceEmpagliflozin | 27 | $29,875 |
| XareltoRivaroxaban | 23 | $20,578 |
| EntrestoSacubitril/Valsartan | 12 | $18,383 |
| Metoprolol Succinate | 308 | $5,379 |
| Atorvastatin Calcium | 255 | $3,589 |
| Rosuvastatin Calcium | 44 | $2,032 |
| Amiodarone Hcl | 21 | $1,538 |
| Valsartan | 38 | $1,487 |
| Ranolazine ErRanolazine | 11 | $1,209 |
| Losartan Potassium | 44 | $766 |
| Furosemide | 123 | $699 |
| Ezetimibe | 11 | $582 |
| Amlodipine Besylate | 97 | $518 |
| Lisinopril | 47 | $382 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Boston
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
- Ignacio Inglessis-AzuajeBoston$545K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.